GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » 3-Year FCF Growth Rate

NurExone Biologic (FRA:J90) 3-Year FCF Growth Rate : -48.40% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic 3-Year FCF Growth Rate?

NurExone Biologic's Free Cash Flow per Share for the three months ended in Dec. 2024 was €-0.02.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -48.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 4 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of NurExone Biologic was -48.40% per year. The lowest was -48.40% per year. And the median was -48.40% per year.


Competitive Comparison of NurExone Biologic's 3-Year FCF Growth Rate

For the Biotechnology subindustry, NurExone Biologic's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's 3-Year FCF Growth Rate falls into.


;
;

NurExone Biologic 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


NurExone Biologic  (FRA:J90) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


NurExone Biologic 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines